Thomson Reuters Cortellis Competitive Intelligence
Read the first installment of this report on Brazil here.
Figure 3A:
Current clinical trial approval timelines in Russia average three to four months. However, unethical conduct in the country has been revealed in surveys and remarks by sponsors. Biogen Idec provided an example at the global clinical trials conference: in 2013, the company shut down all Russian sites for a Phase II trial—representing one quarter of the study’s patients—because investigators did not want their trial income reported to the state employers. Although it does not appear that global sponsors are largely pulling out of Russia, clinical trial initiation has declined in number since its peak in 2012.
SOURCE: Thomson Reuters Cortellis Competitive Intelligence
Read the full report here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.